comprehensive -WSS

comprehensive

author：explore 2025-09-07 17:29:15 - browse：6711

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout Newsletter: CAR

hotspot

WSS

NIH tests clinical research in primary care with $30 million program

Statins may not be needed by millions of people, study suggests

Moderna says combo Covid

EPA limits use of carcinogenic gas for sterilizing medical devices

Study: Why relieving medical debt did not improve financial outcomes

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Statins may not be needed by millions of people, study suggests

Medicare details structure of new drug price negotiation program

NIH tests clinical research in primary care with $30 million program

Bright Health sells Medicare Advantage business to Molina

Cigna wins case to block Amy Bricker's move to CVS

Drug repurposing or repositioning? The language matters

New report analyzes digital physical therapy solutions' effectiveness

Virginia high school admissions case could be legal follow

California wildfire smoke linked to 52,000 early deaths, study says

hotspot

Why depression after traumatic brain injury is distinct

Medical device trials still don't enroll enough women, study finds

Lilly's Alzheimer's drug donanemab backed by FDA advisers

STAT Virtual Event: ASCO Recap, Live!

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Deposition: Sackler embraced plan to conceal OxyContin’s strength

hotspot

focus

leisure time

focus